Related Experiment Video
Updated: Jun 7, 2025

08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.3K
Robust Optimization for Spot-Scanning Proton Therapy based on Dose-Linear-Energy-Transfer Volume Constraints
Jingyuan Chen1, Yunze Yang2, Hongying Feng3
1Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
International Journal of Radiation Oncology, Biology, Physics
|November 17, 2024
Summary
A new dose-LET-volume constraint robust optimization (DLVCRO) method for spot-scanning proton therapy (SSPT) improves organ-at-risk protection in prostate cancer patients. This approach enhances joint dose and linear energy transfer distributions, minimizing adverse events.
Area of Science:
- Medical Physics
- Radiation Oncology
- Computational Biology
Background:
- Traditional spot-scanning proton therapy (SSPT) planning uses separate dose-volume and linear energy transfer (LET) volume constraints.
- This separation can limit the ability to optimize both tumor control and organ-at-risk (OAR) protection simultaneously.
- Prostate cancer treatment planning requires careful balancing of dose and LET to minimize toxicity.
Purpose of the Study:
- To introduce a novel dose-LET-volume constraint robust optimization (DLVCRO) method for SSPT in prostate cancer.
- To achieve a superior joint dose and LET distribution, thereby minimizing adverse events.
- To enhance OAR protection while maintaining target coverage and plan robustness.
Main Methods:
- DLVCRO was developed, treating dose-LET-volume constraints (DLVCs) as soft constraints to shape dose-LET volume histogram (DLVH) curves.
- The method aims to minimize high LET/high dose overlap in OARs and redistribute LET from OARs to targets.
- Ten prostate cancer patients were retrospectively analyzed, comparing DLVCRO with conventional robust optimization (RO) using worst-case analysis and various histogram indices (DVH, LVH, xBDVH).
Main Results:
- DLVCRO significantly improved the joint dose and LET distribution for OAR protection in the nominal scenario compared to RO.
- Physical dose distributions in targets and OARs were comparable between the two methods.
- In the worst-case scenario, DLVCRO demonstrated markedly enhanced OAR protection while maintaining comparable target dose coverage and homogeneity robustness.
Conclusions:
- DLVCRO advances treatment planning from 2D DVH-based to 3D DLVH-based approaches.
- This method enables simultaneous and robust adjustment of dose and LET distributions.
- DLVCRO shows potential as a powerful tool for improving patient outcomes in SSPT.

